Despite the fact that OCI-Ly3 cells that carry oncogenic CARMA1 mutation are resistant to Ibrutinib treatment, we wanted to verify that indeed the oncogenic status of the ABC DLBCL cells independent of their origin determines drug sensitivity. This evidence concerns the gene CARD11 and diffuse large B-cell lymphoma.